Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.

[1]  J. Carles,et al.  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.

[2]  F. Saad,et al.  Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. , 2022, The New England journal of medicine.

[3]  M. Mitterhauser,et al.  Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies , 2022, Molecular cancer.

[4]  B. Sitek,et al.  Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer , 2021, Journal of cellular and molecular medicine.

[5]  S. Shariat,et al.  Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis , 2021, International Journal of Clinical Oncology.

[6]  S. Culine,et al.  Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. , 2021, European urology.

[7]  B. Tombal,et al.  Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study , 2021, ESMO open.

[8]  H. Miyake,et al.  Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents , 2021, International Journal of Clinical Oncology.

[9]  N. Numao,et al.  Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer , 2021, Cancer Chemotherapy and Pharmacology.

[10]  M. Eklund,et al.  Real world treatment utilization patterns in patients with castration-resistant prostate cancer , 2021, Scandinavian journal of urology.

[11]  O. Sartor,et al.  Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study , 2021, Cancers.

[12]  A. D'Amico,et al.  NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  M. Stockler,et al.  [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial , 2021, The Lancet.

[14]  Henk G van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.

[15]  J. Carles,et al.  Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. , 2020, The Lancet. Oncology.

[16]  F. Pouliot,et al.  Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. , 2020, European urology oncology.

[17]  A. Fourrier-Réglat,et al.  Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice. , 2020, Clinical genitourinary cancer.

[18]  J. Pang,et al.  Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis , 2020, Prostate Cancer and Prostatic Diseases.

[19]  F. Saad,et al.  Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. , 2020, Clinical genitourinary cancer.

[20]  K. Kuroiwa,et al.  Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study , 2020, Anti-cancer drugs.

[21]  H. Miyake,et al.  Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer. , 2019, Japanese journal of clinical oncology.

[22]  A. Fourrier-Réglat,et al.  Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort , 2019, British Journal of Cancer.

[23]  N. Numao,et al.  Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan , 2019, AntiCancer Research.

[24]  M. Hendriks,et al.  Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. , 2019, Clinical genitourinary cancer.

[25]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[26]  S. Sakamoto,et al.  Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer , 2019, Urologia Internationalis.

[27]  S. Shariat,et al.  Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. , 2019, Clinical genitourinary cancer.

[28]  H. Miyake,et al.  Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer , 2019, AntiCancer Research.

[29]  Liang Jin,et al.  The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy , 2019, Journal of Cancer.

[30]  E. Kikuchi,et al.  No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer , 2018, Cancer Chemotherapy and Pharmacology.

[31]  M. Oya,et al.  Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel. , 2018, Molecular and clinical oncology.

[32]  H. Miyake,et al.  Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel , 2018, AntiCancer Research.

[33]  M. Yao,et al.  Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel , 2018, BMC Cancer.

[34]  F. Saad,et al.  Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. , 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[35]  M. Parmar,et al.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  R. Hofheinz,et al.  PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study , 2018, World Journal of Urology.

[37]  R. Mathijssen,et al.  Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel , 2017, Oncotarget.

[38]  Yanqing Wang,et al.  Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration‐resistant prostate cancer patients treated with abiraterone , 2017, The Prostate.

[39]  M. Yao,et al.  Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy , 2017, BioMed research international.

[40]  W. Oh,et al.  Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting , 2017, Medical Oncology.

[41]  S. Culine,et al.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.

[42]  C. Prado,et al.  Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later , 2016, Proceedings of the Nutrition Society.

[43]  P. Kantoff,et al.  A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  A. Bergman,et al.  The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. , 2015, European journal of cancer.

[45]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[46]  E. Antonarakis,et al.  Association of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with first‐line docetaxel , 2014, BJU international.

[47]  B. van Calster,et al.  Prognostic impact of baseline serum C‐reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib , 2014, BJU International.

[48]  S. Oudard,et al.  Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. , 2014, European journal of cancer.

[49]  A. Armstrong,et al.  Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G. Pond,et al.  Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. , 2013, Future oncology.

[51]  P. Giannakakou,et al.  Androgen receptor on the move: boarding the microtubule expressway to the nucleus. , 2012, Cancer research.

[52]  C. Rock,et al.  Nutrition and physical activity guidelines for cancer survivors , 2012, CA: a cancer journal for clinicians.

[53]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[54]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[55]  Raghu Kacker,et al.  Random-effects model for meta-analysis of clinical trials: an update. , 2007, Contemporary clinical trials.

[56]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[57]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[58]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[59]  H. Yaegashi,et al.  Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy , 2021, In Vivo.